Myung In Pharmaceutical LTD. (KRX:317450)
South Korea · Delayed Price · Currency is KRW 45,400
-1,750 (-3.71%)
At close: Aug 21, 2026
KRX:317450 Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 293,031 | 287,254 | 269,435 | 242,338 | 225,828 | 209,250 |
Revenue Growth | 4.42% | 6.61% | 11.18% | 7.31% | 7.92% | 11.40% |
Gross Profit Gross Profit Growth | 181,001 | 173,985 | 168,879 | 153,925 | 143,549 | 138,297 |
Operating Income Operating Income Growth | 98,306 | 92,498 | 92,754 | 83,618 | 75,903 | 74,206 |
Net Income Net Income Growth | 88,854 | 81,435 | 68,671 | 74,512 | 57,434 | 59,750 |
Earnings Per Share EPS Growth | 6428.39 | 6717.86 | 6131.00 | 6652.82 | 5128.04 | 5334.82 |
EPS Growth | -7.58% | 9.57% | -7.84% | 29.73% | -3.88% | 31.38% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 470,002 | 509,692 | 260,296 | 187,529 | 142,686 | 120,753 |
Total Debt Total Debt Growth | 982.84 | 1,386 | 2,700 | 3,887 | 4,945 | 5,609 |
Net Cash (Debt) Net Cash Growth | 469,019 | 508,306 | 257,596 | 183,642 | 137,740 | 115,143 |
Net Cash Growth | 70.08% | 97.33% | 40.27% | 33.32% | 19.63% | 80.64% |
Net Cash Per Share Net Cash Per Share Growth | 33932.34 | 41931.84 | 22998.48 | 16396.62 | 12298.25 | 10280.65 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 77,882 | 81,561 | 82,972 | 76,075 | 61,045 | 66,105 |
Capital Expenditures CapEx Growth | -46,088 | -30,039 | -10,189 | -4,647 | -3,402 | -2,697 |
Free Cash Flow Free Cash Flow Growth | 31,794 | 51,522 | 72,783 | 71,428 | 57,643 | 63,407 |
Free Cash Flow Growth | -57.65% | -29.21% | 1.90% | 23.91% | -9.09% | 39.39% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 61.77% | 60.57% | 62.68% | 63.52% | 63.57% | 66.09% |
Operating Margin | 33.55% | 32.20% | 34.43% | 34.51% | 33.61% | 35.46% |
Pretax Margin | 38.48% | 35.55% | 32.69% | 37.99% | 36.23% | 38.12% |
Profit Margin | 30.32% | 28.35% | 25.49% | 30.75% | 25.43% | 28.55% |
FCF Margin | 10.85% | 17.94% | 27.01% | 29.47% | 25.52% | 30.30% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 1000.000 | - | - | 2000.000 | 1000.000 | 1250.000 |
Dividend Per Share Growth | 0% | - | - | 100.00% | -20.00% | -28.57% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 7.06 | 12.35 | - | - | - | - |
P/FCF Ratio | 20.85 | 19.52 | - | - | - | - |
PS Ratio | 2.26 | 3.50 | - | - | - | - |